Japan’s Eisai says that US regulators have granted a priority review for a new application of the firm’s proton pump inhibitor Aciphex. Japan’s Eisai says that US regulators have granted a priority ...
Aciphex is a proton-pump inhibitor that works by decreasing the amount of acid made in the stomach to treat the symptoms of GERD (eg, heartburn, regurgitation of acid, and nausea). Aciphex is also ...
WASHINGTON (DC) - Dr. Reddy's Laboratories violated Eisai Inc.'s patent by introducing a generic version of the gastric-acid inhibitor Aciphex, the Federal Circuit ruled. Judge Rader affirmed the ...
NEW YORK, May 11 (Reuters) - A U.S. court on Friday upheld drug companies seeking to sell cheap versions of the medicine. The court decision was a major victory for Japan-based Eisai, which derives ...
Eisai announced that the FDA has approved Aciphex Sprinkle (rabeprazole sodium) Delayed-Release Capsules for the treatment of gastroesophageal reflux disease (GERD) in children 1–11 years of age for ...
March 13, 2007 — The US Food and Drug Administration (FDA) has approved first-time generic formulations for rabeprazole sodium 20-mg delayed-release tablets and ranitidine HCl 15-mg/mL oral ...
SAN FRANCISCO (MarketWatch) -- Teva Pharmaceutical Industries Ltd. late Friday said a U.S. district court has found that Eisai Co.'s patent for its acid pump inhibitor, Aciphex, is enforceable. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback